PFE Dec 2024 18.000 call
| Previous close | 7.56 |
| Open | N/A |
| Bid | 10.25 |
| Ask | 11.60 |
| Strike | 18.00 |
| Expiry date | 2024-12-20 |
| Day's range | 7.56 - 7.56 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WirePfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK, June 18, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning.
ZacksMerck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
ReutersKansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness. In a lawsuit filed in the District Court of Thomas County, the state said the New York-based drugmaker's alleged false statements violated the Kansas Consumer Protection Act. "Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth," Kansas Attorney General Kris Kobach, a Republican, said in a statement.
